Serum Autotaxin/ENPP2 correlates with insulin resistance in older humans with obesity

Obesity

Volumn 23, Issue 12, 2015, Pages 2371-2376

  Reeves, Valerie L ^a   Trybula, Joy S ^a   Wills, Rachel C ^a   Goodpaster, Bret H ^b   Dubé, John J ^a   Kienesberger, Petra C ^c   Kershaw, Erin E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b FLORIDA HOSPITAL   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; THIAZIDE DIURETIC AGENT; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; GLUCOSE BLOOD LEVEL; PHOSPHODIESTERASE;

ADULT; AGED; ARTICLE; BODY MASS; CORRELATION ANALYSIS; DRUG USE; ENERGY BALANCE; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID HOMEOSTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; PATHOGENESIS; PHENOTYPE; PREDICTION; SEX DIFFERENCE; AGING; ANIMAL; BLOOD; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; WEIGHT LOSS PROGRAM;

ADIPOSITY; AGED; AGING; ANIMALS; BLOOD GLUCOSE; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PHOSPHORIC DIESTER HYDROLASES; WEIGHT REDUCTION PROGRAMS;

EID: 84955193175     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21232     Document Type: Article

References (32)

1. Cornier MA, Dabelea D, Hernandez TL, et al., The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-497.
3. Jung UJ, Choi MS., Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15: 6184-6223.
4. Kershaw EE, Flier JS., Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
5. Maury E, Brichard SM., Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1-16.
6. Boutin JA, Ferry G., Autotaxin. Cell Mol Life Sci 2009; 66: 3009-3021.
7. Nakanaga K, Hama K, Aoki J., Autotaxin-an LPA producing enzyme with diverse functions. J Biochem 2010; 148: 13-24.
8. Yuelling LM, Fuss B., Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochim Biophys Acta 2008; 1781: 525-530.
9. Ferry G, Tellier E, Try A, et al., Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 2003; 278: 18162-18169.
10. Gesta S, Simon MF, Rey A, et al., Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. J Lipid Res 2002; 43: 904-910.
11. Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M., Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 2009; 284: 216-221.
12. Aoki J, Taira A, Takanezawa Y, et al., Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 2002; 277: 48737-48744.
13. Watanabe N, Ikeda H, Nakamura K, et al., Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007; 41: 616-623.
14. Choi JW, Herr DR, Noguchi K, et al., LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010; 50: 157-186.
15. Lin ME, Herr DR, Chun J., Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediators 2010; 91: 130-138.
16. Yung YC, Stoddard NC, Chun J., LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res 2014; 55: 1192-1214.
17. Archbold JK, Martin JL, Sweet MJ., Towards selective lysophospholipid GPCR modulators. Trends Pharmacol Sci 2014; 35: 219-226.
18. Tigyi G., Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010; 161: 241-270.
19. Rancoule C, Dusaulcy R, Treguer K, Gres S, Attane C, Saulnier-Blache JS., Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie 2014; 96: 140-143.
20. Rancoule C, Attane C, Gres S, et al., Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia 2013; 56: 1394-1402.
21. Nishimura S, Nagasaki M, Okudaira S, et al., ENPP2 contributes to adipose tissue expansion and insulin resistance in diet-induced obesity. Diabetes 2014; 63: 4154-4164.
22. Dusaulcy R, Rancoule C, Gres S, et al., Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 2011; 52: 1247-1255.
23. Federico L, Ren H, Mueller PA, et al., Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol 2012; 26: 786-797.
24. Rancoule C, Dusaulcy R, Treguer K, et al., Depot-specific regulation of autotaxin with obesity in human adipose tissue. J Physiol Biochem 2012; 68: 635-644.
25. Boucher J, Quilliot D, Praderes JP, et al., Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 2005; 48: 569-577.
26. Dube JJ, Amati F, Toledo FG, et al., Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide. Diabetologia 2011; 54: 1147-1156.
27. Dube JJ, Amati F, Stefanovic-Racic M, Toledo FG, Sauers SE, Goodpaster BH., Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited. Am J Physiol Endocrinol Metab 2008; 294: E882-E888.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
29. Nakai Y, Ikeda H, Nakamura K, et al., Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin Biochem 2011; 44: 576-581.
30. Nakamura K, Igarashi K, Ide K, et al., Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta Int J Clin Chem 2008; 388: 51-58.
31. Nakamura K, Ohkawa R, Okubo S, et al., Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clin Biochem 2007; 40: 274-277.
32. Rachakonda VP, Reeves VL, Aljammal J, et al., Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity 2015; 23: 965-972.